Do you have patients with a history of cardiac events and difficult to treat cholesterolemia?
Consider these resources from SCAI on PCSK9 inhibitors:
Featuring Michael Davidson, MD from the University of Chicago Pritzker School of Medicine on “LDL Management: Guideline Recommendations,” covering the 2018 AHA/ACC Multicity Guideline on the Management of Blood Cholesterol.
Other topics include:
- Case Presentation, Emmanouil S. Brilakis, MD, PhD, FSCAI
- The Impact of PCSK-9 Inhibition of Coronary Plaque: GLAGOV and Beyond, Subhash Banerjee, MD, FSCAI,
- PCSK-9 Inhibition: Clinical Trial Data, Payal Kohli, MD
- Lipid Lowering in the COVID Era, Thomas Knickelbine, MD, FSCAI
This activity is sponsored by SCAI and supported by Amgen.
Other resources from SCAI
Sharing knowledge, experience, research and knowledge.